## SHERIDAN CAPITAL PARTNERS

## WHO WE ARE

Sheridan Capital Partners is a Chicago-based lower middle market private equity firm focused exclusively on building leading companies within the healthcare industry.

- Founded in 2012
- Partners have over 50 years of collective private equity experience
- The principals of Sheridan are dedicated to an open, synergistic approach to partnership
- We pride ourselves on the long-term relationships we build with our partners

## **OUR APPROACH**

We partner with strong management teams to implement a value creation framework and drive profitable growth:

- Support and supplement existing management talent where required
- Establish the operating model necessary to effectively scale the business
- Identify accretive M&A opportunities provide capital and strategy necessary for integration

## **INVESTMENT CRITERIA**

Q	Transaction Types			
	Control positions in N. American based healthcare businesses			
	Partial recapitalizations or buyouts			
	Transaction Size			
	Target platform EBITDA of \$3 to \$20 million			
	Target equity investments of \$15 to \$100 million (including add-ons)			
	Industry Focus + Preferred Subsectors			
	Healthcare Providers			
	Healthcare Outsourced Services			
	Consumer Health & Products			
1 2	Company Characteristics			
	Founder-owned, entrepreneurially led businesses			
	Strong business model, with a history of consistent growth and profitability			
	Attractive underlying secular growth trends and market fragmentation			

Diversified client bases, with no/limited FDA approval risk or biopharmaceutical risk

Jonathan B. Lewis Partner 312.324.0879 jonathan.lewis@sheridancp.com

Christopher S. McCrory Principal 312.262.5039 christopher.mccrory@sheridancp.com Sean M. Dempsey Partner 312.273.6508 sean.dempsey@sheridancp.com

Brian M. McGregor Vice President 872.810.0282 brian.mcgregor@sheridancp.com Nicholas E. Rowland Partner 312.273.1590 nicholas.rowland@sheridancp.com

Matthew J. Collins Vice President 872.264.7052 matthew.collins@sheridancp.com Alexandra M. Kier Director of Business Development 312.273.5353 alexandra.kier@sheridancp.com

**Brent H.W. Blankenship** Vice President – Business Development 872.810.0315 brent.blankenship@sheridancp.com

<b>FirstEnroll</b>	INDUSTRY HC Third Party Administration	INVESTMENT DATE June 2023	ADD-ON CRITERIA US or Canada
	INDUSTRY Revenue Cycle Management	INVESTMENT DATE January 2023	ADD-ON CRITERIA US or Canada
ADVI	INDUSTRY Pharma Services	INVESTMENT DATE December 2022	ADD-ON CRITERIA Global
RSA	INDUSTRY Medical Equipment Servicing	investment date May 2022	ADD-ON CRITERIA Global
<b>SimiTree</b>	INDUSTRY Post-acute consulting and RCM	INVESTMENT DATE May 2021	ADD-ON CRITERIA US or Canada
DAShealth	INDUSTRY Healthcare MSP	INVESTMENT DATE February 2021	ADD-ON CRITERIA US or Canada
TARRYTOWN EXPOCARE PHARMACY	INDUSTRY IDD Pharmacy	INVESTMENT DATE December 2019	ADD-ON CRITERIA US
ORAL SURGERY PARTNERS	INDUSTRY Oral Surgery	INVESTMENT DATE May 2019	ADD-ON CRITERIA Central/Eastern US
ATLANTIC VISION PARTNERS	INDUSTRY Ophthalmology and Optometry	INVESTMENT DATE April 2019	ADD-ON CRITERIA Southeastern US
	INDUSTRY Physical Therapy	INVESTMENT DATE August 2018	ADD-ON CRITERIA Southwestern US
SPEND MEND	INDUSTRY Cost Cycle Management	INVESTMENT DATE January 2018	ADD-ON CRITERIA US or Canada <i>Recapitalized in 2022</i>
DOCS DERMATOLOGISTS OF CENTRAL STATES	<b>INDUSTRY</b> Dermatology	INVESTMENT DATE April 2017	ADD-ON CRITERIA Realized
canadian orthodontic partners	<b>INDUSTRY</b> Orthodontics	INVESTMENT DATE November 2016	ADD-ON CRITERIA Realized
	INDUSTRY Sports Nutrition Distribution	INVESTMENT DATE February 2016	ADD-ON CRITERIA Realized
SMILE DOCTORS	INDUSTRY Orthodontics	INVESTMENT DATE September 2015	ADD-ON CRITERIA Realized
	INDUSTRY Biologics	INVESTMENT DATE September 2013	ADD-ON CRITERIA <i>Realized</i>
	INDUSTRY Veterinary Pharmacy	INVESTMENT DATE December 2012	ADD-ON CRITERIA <i>Realized</i>